The new venture, between the Association of the British Pharmaceutical Industry (ABPI) and Ashton, Leigh and Wigan PCT, moves into a new area – working together on a pilot scheme to develop commissioning plans.
The aim of the new scheme is to bring additional resource to the PCT as it develops its commissioning plans, which are designed to compare patients’ conditions and needs against the treatment they are receiving and finding better ways of providing it. It will also allow pharmaceutical companies to deepen their knowledge and understanding of how they can help other NHS organisations to implement this new agenda.
“Targeted and ethical joint working between the industry and the NHS can bring great benefits to patients and the NHS, and this latest co-operative venture is a prime example of the sort of endeavour that we and the Government are seeking to encourage,” said Martin Anderson, ABPI Director of NHS Policy and Partnerships.
“The new guidance and its associated toolkit, issued jointly by the Department of Health and the ABPI, encourage PCTs to work with the industry in appropriate areas. It is in everyone’s interest to do so – as this latest agreement with Ashton, Leigh and Wigan PCT demonstrates.”
Peter Rowe, Chief Executive of Ashton, Leigh and Wigan PCT, said: “We are determined to improve healthcare and really tackle health inequalities. The appropriate use of modern medicines is central to achieving this. We believe that joint working with pharmaceutical companies in line with the Best Practice Guidance will bring new expertise and resources, and will make a significant contribution to our ambition to become world class commissioners.”
Once the commissioning pilot study has been completed, the results will be shared with ABPI member companies and other NHS organisations. The ABPI and Ashton, Leigh and Wigan PCT have worked together before on different projects.
The joint DH-ABPI toolkit to encourage joint working initiatives was unveiled on March 5 at the inaugural NHS Confederation PCT Network Conference in London.
For further information, please contact: ABPI Press office 020 7747 1410